DexCom (NASDAQ:DXCM) Cut to “Hold” at StockNews.com

StockNews.com cut shares of DexCom (NASDAQ:DXCM) from a buy rating to a hold rating in a research note published on Tuesday.

Other equities research analysts have also issued research reports about the stock. Raymond James boosted their price target on shares of DexCom from $147.00 to $151.00 and gave the company a strong-buy rating in a report on Tuesday, January 23rd. Royal Bank of Canada assumed coverage on shares of DexCom in a report on Tuesday, March 12th. They issued an outperform rating and a $165.00 price target for the company. Citigroup boosted their price target on shares of DexCom from $148.00 to $161.00 and gave the company a buy rating in a report on Wednesday, April 3rd. Finally, UBS Group boosted their price target on shares of DexCom from $153.00 to $163.00 and gave the company a buy rating in a report on Wednesday, April 10th. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of Moderate Buy and a consensus price target of $141.67.

DexCom Price Performance

DexCom stock opened at $124.34 on Tuesday. The stock has a market cap of $49.24 billion, a price-to-earnings ratio of 80.22, a price-to-earnings-growth ratio of 2.37 and a beta of 1.20. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.84 and a quick ratio of 2.48. DexCom has a 1 year low of $74.75 and a 1 year high of $142.00. The firm has a 50-day moving average of $131.13 and a two-hundred day moving average of $118.30.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million during the quarter, compared to analysts’ expectations of $911.20 million. DexCom had a net margin of 16.82% and a return on equity of 31.38%. On average, research analysts forecast that DexCom will post 1.76 earnings per share for the current year.

Insider Buying and Selling at DexCom

In other DexCom news, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the transaction, the chief financial officer now owns 71,142 shares in the company, valued at approximately $8,304,405.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other DexCom news, EVP Matthew Vincent Dolan sold 1,990 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $137.81, for a total transaction of $274,241.90. Following the transaction, the executive vice president now owns 42,377 shares in the company, valued at approximately $5,839,974.37. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jereme M. Sylvain sold 3,363 shares of the company’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $116.73, for a total transaction of $392,562.99. Following the completion of the sale, the chief financial officer now directly owns 71,142 shares in the company, valued at $8,304,405.66. The disclosure for this sale can be found here. In the last quarter, insiders have sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is owned by corporate insiders.

Institutional Trading of DexCom

Large investors have recently made changes to their positions in the business. DSM Capital Partners LLC purchased a new stake in shares of DexCom in the 4th quarter valued at $28,000. Riverview Trust Co purchased a new stake in shares of DexCom in the 1st quarter valued at $32,000. Valley National Advisers Inc. boosted its holdings in shares of DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 103 shares during the last quarter. MV Capital Management Inc. boosted its holdings in shares of DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 138 shares during the last quarter. Finally, Smithfield Trust Co boosted its holdings in shares of DexCom by 103.1% in the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after acquiring an additional 165 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.